English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Viability of autoantibody-targets: How to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis

MPS-Authors
/persons/resource/persons61202

Mayer,  Marie Cathrin
Department: Neuroimmunology / Wekerle, MPI of Neurobiology, Max Planck Society;

/persons/resource/persons38897

Hohlfeld,  Reinhard
Department: Neuroimmunology / Wekerle, MPI of Neurobiology, Max Planck Society;

/persons/resource/persons38991

Meinl,  Edgar
Department: Neuroimmunology / Wekerle, MPI of Neurobiology, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Mayer, M. C., Hohlfeld, R., & Meinl, E. (2012). Viability of autoantibody-targets: How to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis. JOURNAL OF THE NEUROLOGICAL SCIENCES, 319(1-2), 2-7. doi:10.1016/j.jns.2012.05.018.


Cite as: https://hdl.handle.net/11858/00-001M-0000-000F-E5A4-5
Abstract
The growing complexity number of multiple sclerosis (MS) therapy emphasizes the need for an individualized approach, tailoring therapy to the needs of the individual patient. There is evidence supporting the immunopathological heterogeneity of MS, based on the analysis of biopsy and autopsy tissues. In clinical practice it is impossible to differentiate between the pathological subtypes of MS, because blood or CSF markers of pathological heterogeneity are lacking. Identification of such markers would be important, because "tailored therapy" and "biomarkers for patient stratification" may be considered as two sides of the same coin. In this article, we discuss the emerging role of autoantibodies as potential biomarkers, focusing on myelin oligodendrocyte glycoprotein (MUG) as one of the best characterized autoantigens in MS. In addition, we discuss several strategies for the identification of novel candidate autoantigens. (C) 2012 Elsevier B.V. All rights reserved.